There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atossa Genetics (NASDAQ:ATOS) and CTI BioPharma (NASDAQ:CTIC) with bullish sentiments.
Atossa Genetics (ATOS)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics today and set a price target of $10. The company’s shares opened today at $2.59, close to its 52-week low of $2.01.
McCarthy noted:
“Atossa announced the company is advancing its intraductal microcatheter technology for delivery of immune-oncology agents (including CAR-T) into a pre-clinical program with Translational Drug Development, LLC (private).”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.5% and a 43.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Atossa Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
CTI BioPharma (CTIC)
In a report released today, Leah R. Cann from Oppenheimer assigned a Buy rating to CTI BioPharma, with a price target of $4. The company’s shares opened today at $3.
Cann wrote:
“We are delaying our estimated launch of CTIC’s product candidate pacritinib until 2022. Our financial outlook for 2018-19 is basically unchanged. For 2020-24, our revenue forecast is being reduced by 55.0%, 88.0%, 86.2%, and 51.0%, respectively, to account for the delay for pacritinib. We are lowering estimated SG&A owing to the delay, but estimated R&D expenses remain basically unchanged. R&D was scaled to include investment in additional development, which we estimate suffices to cover the newly announced phase III study. The net effect is an increase in our estimated loss per share from ($0.75) to ($0.94) for 2020 and from ($0.12) to ($1.19) for 2021. We no longer estimate that CTI will be and are lowering our EPS to loss per share forecasts.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 27.1% and a 60.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
CTI BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $7, which is a 133.3% upside from current levels. In a report issued on July 10, JMP Securities also maintained a Buy rating on the stock with a $8 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
